Sometimes, a dispute with a consumer movement comes along that has profound implications for far more than the people in it. I think the dramatic clash between the ME/CFS patient community and a
A study piqued my curiosity in a news feed recently. Yoga could reduce depression symptoms, researchers said – but only if you expected it to (Uebelacker 2018). Yoga for depression, it turns out, is
A very influential nutrition trial just tanked. It was retracted from the New England Journal of Medicine (NEJM) on 13 June, and re-published with new analyses and toned-down conclusions. Both Gina Kolata, writing in
“I remember wheeling down this long, narrow corridor into my office, just a confused, scared mess, but I had to confront him.” Phil Vardy was a young medical researcher in Sydney that day in 1982. The
The case of the missing neurological drug trials remains shrouded in mystery. Nearly 48,000 people took part in these trials for new drugs for multiple sclerosis, stroke, Alzheimer disease, migraine, epilepsy, insomnia, and Parkinson disease.
A tweet jolted me today. Doublespeak hit the news a few days ago, sending George Orwell’s final masterpiece, Nineteen Eighty-Four, back into a bestseller list. It was the anniversary of Orwell’s death this weekend, too.
It was definitely déjà vu in the media today. Reuters, The Times, Los Angeles Times, and more were back on the “brain training prevents dementia” bandwagon. STAT’s headline was particularly boosterish: Play on! In a
I blame the writing and research impact advice we get. At least in part. It doesn’t prepare us as well as it could for our relationship with machines. When we’re told to think of “the
Many trials end with a whimper. But some end with a bang. Press release, press conference, lots of fanfare – and backlash. The drama of another clinical trial being stopped early burst into public